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Stem cell therapyAmyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder that is characterized by progres-
sive degeneration of motor neurons in the cortex, brainstem and spinal cord. This leads to paralysis, respiratory
insufﬁciency anddeathwithin anaverage of 3 to 5 years fromdisease onset.While the genetics of ALS are becom-
ing more understood in familial cases, the mechanisms underlying disease pathology remain unclear and there
are no effective treatment options. Without understanding what causes ALS it is difﬁcult to design treatments.
However, in recent years stem cell transplantation has emerged as a potential new therapy for ALS patients.
While motor neuron replacement remains a focus of some studies trying to treat ALS with stem cells, there is
more rationale for using stem cells as support cells for dying motor neurons as they are already connected to
the muscle. This could be through reducing inﬂammation, releasing growth factors, and other potential less
understood mechanisms. Prior to moving into patients, stringent pre-clinical studies are required that have at
least some rationale and efﬁcacy in animalmodels and good safety proﬁles. However, given our poor understand-
ing of what causes ALS and whether stem cells may ameliorate symptoms, there should be a push to determine
cell safety in pre-clinicalmodels and then a quick translation to the clinicwhere patient trials will show if there is
any efﬁcacy. Here, we provide a critical review of current clinical trials using either mesenchymal or neural stem
cells to treat ALS patients. Pre-clinical data leading to these trials, as well as those in development are also eval-
uated in terms of mechanisms of action, validity of conclusions and rationale for advancing stem cell treatment
strategies for this devastating disorder.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Amyotrophic lateral sclerosis (ALS) is characterized by progressive
degeneration of motor neurons in the cortex, brainstem and spinal
cord resulting in paralysis and death within an average of 3 to 5 years
from disease onset (Zinman and Cudkowicz, 2011). The majority of
ALS cases are of unknown etiology and sporadic in nature (90–95%)
with no genetic association. However, familial ALS (fALS) also exists
and is associated with genes such as TAR DNA-binding protein 43
(TARDP, representing 2–6% of fALS cases), Cu/Zn superoxide dismutase
1 (SOD1, ~20%) andmost recently discovered C9ORF72, representing an
estimated 34% of all fALS cases (van Blitterswijk et al., 2012;Wijesekera
and Leigh, 2009). Although understanding themechanism and function
of C9ORF72 and its role in fALS has recently come to the forefront of ALS
research, previous studies have primarily relied on fALS cases caused by
point mutations in the SOD1 gene. Toxic “gain of function”mutations in
the SOD1 gene in transgenic rodents result in ALS-like phenotypes that
have enabled researchers to study disease pathophysiology. While the
SOD1G93A transgenic model and other rodent models of ALS have pro-
vided insight into disease mechanisms, the cause of motor neuron
death in the more prevalent cases of sporadic ALS is still unknown.
ALS patients experience upper limb, lower limb or bulbar onset, with
variable involvement of upper and lower motor neurons and subse-
quently differing rates of disease progression (Kiernan et al., 2011;
Ravits and La Spada, 2009). This heterogeneity of ALS makes it difﬁcult
to identify the mechanisms of disease origin and to develop successful
therapies. Currently, ALS has no available pharmacological treatment
options that offer long-term efﬁcacy. After half a century of trials and
testing of over 150 different therapeutic agents or strategies in preclin-
ical models of ALS, Riluzole is the only developed drug that prolongs pa-
tient survival time, although by only approximately 2–3 months.
Human embroyonic-derived stem cells and induced pluripotent
stem cells are perhaps the most powerful type of stem cell and hold
great promise for the ﬁeld. Recent advances in adult derived induced
pluripotent stemcells avoids ethical concerns, and could allow for autol-
ogous cell transplantation in the future (Svendsen, 2013). Replacing lost
motor neurons using human pluripotent stem cells is a potential thera-
py for ALS, but relies on transplanting motor neurons expected to sur-
vive and form long-distance projections (from brain to spinal cord,
and/or spinal cord to muscle) with functional connections. This is a
very challenging proposition given the long distances required for axo-
nal outgrowth in the adult compared to development (when themotor
neurons originally make contact with the muscle). In addition, the new
motor neurons are placed in a very toxic environment where all those
around them are dying. Alternatively, transplanting cells that have the
ability to support the survival of existing motor neurons or potentially
“detoxify” the environment is a far more practical idea. Support cell
types can be generated from other tissues such as mesenchymal stem
cells (MSCs) isolated from the bone marrow and neural stem cells
(NSCs) isolated from fetal brain. These cells are not as likely to make
primitive tumors as those derived from pluripotent cells. They are a
safer potential product and have provided a much faster path to the
clinic — although pluripotent stem cell research is developing rapidly
and clearly this ﬁeld will expand enormously in the coming years.There have been several advancements using MSCs and NSCs, all of
which rely on using the stem cells to stimulate the survival of existing
motor neurons rather thanmotor neuron replacement itself.Mesenchy-
mal and neural stem cells have been used to generate immunomodula-
tory cells, growth factor-releasing cells, functional support cells such as
glia, or GABAergic interneurons to modify motor neuron survival and
activity (Gowing and Svendsen, 2011; Lunn et al., 2009; Maragakis,
2010; Papadeas andMaragakis, 2009). Here we discuss these therapeu-
tic approaches and present a detailed synopsis of completed, current
and future clinical trials that show the potential of mesenchymal and
neural stem cells for the treatment of ALS (summarized in Table 1). An-
other recent review has also included many studies in the eastern aca-
demic press and provides an alternative view of current efforts to use
stem cells to treat this devastating disorder (Meamar et al., 2013). Fur-
thermore, for additional reference, “The ALSuntangled Group” has been
instrumental in stimulating discussions and raising the awareness of
certain clinical trials that have only been brieﬂy mentioned here
due to minimal pre-clinical data and/or arguable shortcomings in
trial design and execution (The ALSuntangled group (2010)).
Clinical trials
Mesenchymal/blood-derived stem cells for ALS
MSCs are multipotent adult stromal stem cells of mesodermal
lineage that can be easily isolated from various adult connective tissues
including bone marrow and adipose tissue and subsequently expanded
in vitro to provide large numbers of cells (de Girolamo et al., 2013;
Deans and Moseley, 2000; Giordano et al., 2007; Laroni et al., 2013;
Pittenger et al., 1999; Prockop, 1997). MSC are a very attractive
candidate for cell therapy as they avoid the ethical and practical issues
of embryonic and fetal-derived stem cells and provide the possibility
of autologous transplantation. In most cases their mode of action for
central nervous system (CNS) disorders is thought to be through
transient effects on either inﬂammation or neuronal cell survival,
partially through the release of growth factors and cytokines. There
are few reports of robust MSC survival for more than a few weeks
following transplantation, although this remains an area of debate
(Castro et al., 2002; Himes et al., 2006; Li et al., 2001). A recent review
of clinical trials using intravascular delivery of MSCs for various condi-
tions concluded that MSC therapy appeared safe but that larger, well-
controlled clinical trials with a rigorous reporting systemwere required
to further conﬁrm this safety (Lalu et al., 2012).
Intraparenchymal spinal cord delivery of MsC: The Mazzini Clinical Trials
Overview
In 2003, Mazzini and colleagues performed some of the world's ﬁrst
clinical studies to determine the safety and tolerability of direct
intraparenchymal transplantation of MSCs (or any cell type) to treat
ALS. MSCswere isolated from allogeneic ALS patient bonemarrow aspi-
rates via a Percoll gradient centrifugation protocol and expanded in
adherent cultures with medium containing fetal bovine serum. The
authors stated that the ﬁnal cellular product did not express
Table 1
Summary of past, ongoing and potential stem-cell based clinical trials for ALS.
Trial name Treatment cell type Cell speciﬁcs Delivery method Trial status Pre-clinical rationale for clinical translation
Mazzini MSC Autologous, derived from
patient bone marrow
Spinal cord injections Phase I complete,
no current studies
N/A
Brainstorm MSC Autologous, derived from
patient bone marrow
Intrathecal, intramuscular Phase I complete,
Phase lla current
In vivo secretion of neurotrophic factors,
beneﬁcial effects in Parkinson's and
Huntington's disease rodent models
Martinez Stem cells Autologous, derived from patient blood Frontal cortex injections N/A N/A
Neuralstem NSC Human fetal spinal cord (at 8 weeks) Spinal cord injections Phase I complete,
Phase II current
Enhanced survival of spinalmotor neurons
in rats
Q Therapeutics GRP Human fetal forebrain (at 17–24 weeks) Spinal cord injections Preclinical Beneﬁcial effects on motor function,
lifespan and spinal motor neurons,
decreased microgliosis in rats; using rat
GRPs
Cedars-Sinai hNPC releasing GDNF Human fetal cortex (at 8–15 weeks) Spinal cord injections Preclinical GDNF secretion in vivo enhances survival
of spinal motor neurons in rats
Vescovi NSC Human fetal (unspeciﬁed) Spinal cord injections Phase I current N/A
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CD29, CD44, CD105, CD166 and retained the capacity to be differentiat-
ed into osteoblasts, chondroblasts and adipocytes, although this data
was not shown in any detail (Ferrero et al., 2008; Mazzini et al., 2003;
Mazzini et al., 2003; Mazzini et al., 2008). Remarkably, there was no
published pre-clinical data supporting either efﬁcacy or a mechanism
of action for these cells following injection to the spinal cord of animals,
although some animal studieswere published following the clinical trial
(see next section).
In an initial clinical study, seven ALS patients were transplanted
with variable numbers of MSCs (7–152 × 106 cells) into the thoracic
spinal cord with varying numbers of injection sites (2–5 sites). While
there was no functional improvement over-time following MSC
transplantation, no serious side-effects and no detrimental effects on
neurological function were reported and the authors concluded that
the transplantation of these cell suspensions into the human ALS spinal
cord was safe and well tolerated Mazzini et al., 2003. In patient follow-
up studies more than four years after surgery, no signs of toxicity or
abnormal cell growthwere detected and itwas suggested that the treat-
ment might have beneﬁted four patients (Mazzini et al., 2006; Mazzini
et al., 2008). However, Badayan and Cudkowicz report that the small
sample size, disease variability in selected patients, lack of control
groups, inconsistency in the cell number administered to the patients,
and incomplete data presentation prevented a deﬁnitive conclusion
on MSC safety and efﬁcacy. Hence, they suggested that the lack of pre-
clinical data supporting the approach should preclude further studies
in ALS patients. (Badayan and Cudkowicz, 2008).
Though data from the initial clinical trial showed no overt functional
effects, a second Phase I clinical trial was conducted with expanded
patient numbers using the same methods as described in the original
trial. Twenty patients were selected from 270 clinically deﬁnite and
probable ALS patients, who were observed between September, 2003
and June, 2006. However, due to patient dropout and exclusions based
on other criteria after the start of the study, the ﬁnal cohort included
only 10 patients (Mazzini et al., 2010). In a separate long-term safety
study, a group of 19 ALS patients enrolled in two consecutive Phase I
clinical trials between 2001 and 2003 and were followed for up to
9 years after surgery (Mazzini et al., 2012). From these patients, no corre-
lation was found between the cell dose or number of injection sites and
the severity and duration of side-effects. Importantly, neuroradiologic
analysis demonstrated a lack of tumor formation and no abnormal cell
growth. While ALS disease progression in the majority of patients did
not appear to be slowed by the MSC transplant, it did not accelerate
disease progression and the results from these studies show that this
treatment is safe and does not have any major immediate or long-term
harmful consequences.Pre-clinical trials: Using MsC in proof-of-concept animal studies
Since the start of the Mazzini Clinical Trials, a number of studies
in animal models of ALS have investigated the therapeutic poten-
tial of MSCs administered either peripherally or injected directly
into the spinal cord. As MSC graft survival is seldom observed in af-
fected CNS tissues following transplantation, the beneﬁcial effects
on disease pathology have often been attributed to transient im-
munomodulatory capacities or trophic factor production by grafted
cells. However, in recent studies, bone marrow or adipose-derived
murine MSCs were shown to survive in the CNS of SOD1G93A mice
following intravenous administration (Marconi et al., 2013; Uccelli
et al., 2012). The administration of bonemarrow-derivedMSCs to symp-
tomatic ALS mice halted the decline in body weight, delayed the loss of
motor function and extended lifespan by 17 days. Adipose-derived
MSCs did not affect lifespan, but delayed the deterioration of motor per-
formance and transiently increased the number of surviving motor neu-
rons in ALSmice. Although reporter-labeledMSCs survived and appeared
to have functional effects, the results could have been further strength-
ened by examining cell-type speciﬁc markers, performing histology on
sham-treated controls to deﬁne background staining, and providing
both low and high magniﬁcation images of grafted cells. Moreover, as
MSCs administered into the circulation can often associate with blood
vessel surfaces, using endothelial cell markers and confocal microscopy
would discriminate the transplant location between CNS parenchyma
and vasculature to assure that the cells indeed entered and survived in
the CNS.
Using a different approach, the Mazzini group has now shown that
human bone marrow-derived MSCs can be injected directly into the
lumbar spinal cord of SOD1G93A transgenic mice (Vercelli et al., 2008).
Though the title of this report implies that the MSCs had a robust effect
in the ALS animal model, the data was less convincing.While stereolog-
ical quantiﬁcation revealed that transplantation of humanMSCs result-
ed in a 1.5 and 2.5 fold increase in the number of cresyl violet-stained
motor neurons in treated females and males, respectively, there were
no signiﬁcant beneﬁt on functionalmotor behavior or survival in female
transgenic mice. Furthermore, the delayed motor function decline and
increased survival reported for MSC-treated male SOD1G93A mice was
confounded as the study did not follow all animal groups to disease end-
point. A better powered study and a Kaplan–Meier survival curvewould
more accurately determine the beneﬁt of this treatment on motor neu-
ron survival and function (Scott et al., 2008). In addition, rather than la-
beling human cells with commonly used human-speciﬁc antibodies, a
gold standard to detect human cells grafted into animals, cells were la-
beled with a dye (bisbenzimide) prior to transplantation. This dye and
others have been shown to transfer from the labeled transplanted
cells into host cells (Iwashita et al., 2000). Thus, better evaluation of
130 G.M. Thomsen et al. / Experimental Neurology 262 (2014) 127–137grafted cell detection must occur to conclusively determine the pres-
ence of human MSCs in the mouse CNS in these studies.
Intrathecal transplantation of MSCs induced to secrete neurotrophic factors
(MSC-NTFs): BrainStorm Clinical Trial (NurOwn™)
Rationale and proof-of-concept studies
Several pre-clinical and clinical trials have used human bone
marrow stromal-derived MSCs that are differentiated into specialized
neuron-supporting cells to stably secrete neurotrophic factors (MSC-
NTFs). These cells, from BrainStorm Cellular Therapeutics, have been
trademarked as NurOwn™ since they can be used for autologous adult
stem cell therapy. They have been shown to exhibit MSC markers, dis-
play spindle-like cell morphology, form single-cell-derived colonies,
readily differentiate into adipocytes and osteoblasts, and have the ca-
pacity to express a number of neural genes. (Blondheim et al., 2006).
Sadan and colleagues later described the differentiation of these
humanMSCs into cells that express the astrocytemarkers glial ﬁbrillary
acidic protein (GFAP) and glutamine synthase, and that secrete brain-
derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic
factor (GDNF) and insulin-like growth factor-1 (Sadan et al., 2009).
Beneﬁcial effects were observed after intrastriatal transplantation of
these cells into animal models of Parkinson's disease and Huntington's
disease (Sadan et al., 2009; Sadan et al., 2012). In the 6-OHDA lesion
model of Parkinson's disease, MSC transplants alone had no protective
effect on pathology. In contrast, tyrosine hydroxylase-positive staining
increased and rotational behavior decreased in animals treated with
MSC-NTF compared to vehicle-treated controls. However, tissue analy-
sis using a human-speciﬁc marker revealed very little survival 50 days
following transplantation of the MSC-NTF cells. As MSC-NTFs were
transplanted 24 h following injury and they do not seem to survive
over time, these results indicate that the amelioration in pathology is
likely due to the transient production of trophic factors. This raises the
question of whether this treatment would be efﬁcient in a chronic
model of neurodegeneration. In the Huntington's disease studies, trans-
plantation of MSC-NTF resulted in amelioration of apomorphine-
induced rotation and increased striatum size compared to control. In
contrast to their previous work, where transplanted cells were identi-
ﬁed using human-speciﬁc markers, here the transplanted cells were la-
beled with the general membrane marker, PKH-26, for identiﬁcation.
While thismethod showed signiﬁcant cell survival at 6 weeks following
transplantation, no representative pictures of grafted cells were provid-
ed. To date, there are no peer-reviewed, proof-of-concept studies using
these cells in an ALS animal model and therefore it is extremely difﬁcult
to assess the mechanism of action or discuss pre-clinical rationale for
their use in the treatment of motor neuron degeneration. Nonetheless,
the autologous transplantation of MSC-NTF in ALS patients is currently
under investigation and described below.
Overview
In 2010, a Phase I/II open-safety clinical trial by Karussis and col-
leagues at the Hadassah Medical Center in Jerusalem, Israel showed
that intrathecal and intravenous administration of autologous bone-
marrow-derived MSCs into ALS patients is feasible and safe (Karussis
et al., 2010). In this study, patients with ALS or multiple sclerosis were
treated either via a standard lumbar puncture (~55 × 106, ~63 × 106
MSCs, respectively) or intravenously (~24 × 106 MSCs for both ALS
and MS patients). While the deﬁnitive survival of injected cells was
not shown, this treatment induced immediate immunomodulatory ef-
fects andwas deemed safe. Although this studywas not designed to de-
tect therapeutic efﬁcacy of this treatment, encouragingly, ALS patient
ALSFRS scores remained stable for up to 6 months following treatment.
A more recent Phase I/II clinical trial by the Karussis group and
BrainStorm Cellular Therapeutics evaluated the safety, tolerability
and therapeutic effects of transplanting MSC-NTF cells (used in the
Parkinson's and Huntington's disease animal studies described above)into ALS patients. Twelve patients affected by early stage or progressive
ALS were transplanted either intramuscularly or intrathecally with a sin-
gle dose of MSC-NTF cells. This clinical trial spanning June 2011 to March
2013 is not yet published but details are found at (ClinicalTrials.gov
NCT01777646). More recently, a Phase IIa dose-escalating trial has been
designed to evaluate the safety and preliminary efﬁcacy of MSC-NTF cell
therapy at various doses in ALS patients. Beginning in 2013, twelve ALS
patients in three cohorts were administered MSC-NTF in a combined
therapeutic approach of both intramuscular and intrathecal injections
with increasing doses. Detailed results of these ongoing clinical trials
have not yet been published, thus no conclusion on the safety and efﬁcacy
of this approach canbemade.While these studies are interesting, they are
all open-label and therefore a well-controlled double blind Phase II clini-
cal study is required to avoid observer bias and placebo effects. Addition-
ally, the cell administration methods are different to the pre-clinical
studies transplanting these cells in other disease models directly into
the striatum. Therefore, it remains to be seen whether the chosen routes
of administration are optimal for MSC-NTF to migrate, survive and exert
maximal beneﬁcial effects in the brain and spinal cord regions largely af-
fected by ALS.
Martinez Clinical Trial: Frontal cortex transplantation of blood-derived
stem cells
There has been one published trial from the Hospital San Jose
Tecnologico de Monterrey in Mexico in which blood-derived stem
cells were transplanted into the frontal cortex of ALS patients to target
the upper motor neurons (Martinez et al., 2009). The rationale for this
trial, however, was not clear. There was no pre-clinical animal data to
show efﬁcacy when similar blood-derived stem cells were transplanted
into the cortex, questioning theprogression of this technique to the clin-
ic. There has been no evidence of efﬁcacy of the procedure in patients
(who were required to pay a minimum of $18,000 for participation in
the trial) and there have been no reports of subsequent clinical trials
using this technique. For further critical review of this study, see The
ALSuntangled Group (2010).
Mesenchymal stem cells for ALS: Additional considerations
While MSCs are of great interest to the ALS community, the above
studies are often associated with technical caveats and insufﬁcient in-
formation supporting a delivery route and a rationale for their use in
ALS. To our knowledge,there is no robust pre-clinical data in a relevant
ALS diseasemodel detailing the long-term safety, in vivo differentiation,
dosing and biological activity of human MSCs proposed for use in
patients.
However, MSCs do have several attributes that make them a
promising candidate for cell-based therapies. First, they are easy
to derive and provide an abundant source of cells. In addition,
they are not immunogenic, they release growth factors and have
immune-suppressive features (Aggarwal and Pittenger, 2005; Di
Nicola et al., 2002; English and Wood, 2013; Le Blanc, 2003; Stagg
and Galipeau, 2013). In fact, several clinical trials are evaluating
the potential of systemic administration of MSCs for the treatment
of inﬂammatory diseases such as graft-versus-host disease, multiple
sclerosis and Crohn's disease (De Miguel et al., 2012; Figueroa et al.,
2012). Together these promising attributes support the use of MSCs
for cell therapy in ALS, which may also show inﬂammatory changes
during progression. However, prior to further pursuit as a therapeu-
tic approach for ALS, signiﬁcant efforts should focus on demonstrat-
ing their therapeutic potential and putative mode of action in a
well-powered and controlled pre-clinical study using a relevant
ALS disease model. Even though this data is not available, MSC safety
and ease of production have led to several current and completed
Phase I clinical trials for determining the safety of intravenous, intraven-
tricular or intrathecal delivery of MSCs to ALS patients (NCT01609283;
131G.M. Thomsen et al. / Experimental Neurology 262 (2014) 127–137NCT01142856; NCT01759784; NCT01759797; NCT01771640). While
dramatic clinical improvement has yet to be seen in any of these trials,
they will at least provide deﬁnite data about the safety of MSCs for ALS
patients and they may lead to larger blinded trials to uncover any dis-
ease modifying effects of these cells.
Neural stem cells for ALS
ALS mouse studies have shown that motor neuron disease is a non-
cell-autonomous process, as expression of mutant SOD1 within mouse
motor neurons alone does not lead to an ALS phenotype (Jaarsma
et al., 2008; Yamanaka et al., 2008a). Rather, non-neuronal cells such
as glia also contribute to ALS pathology, which is demonstrated by the
fact that deletion of the SOD1 mutation from microglia and astrocytes
resulted in enhanced survival of transgenic ALS mice (Boillee et al.,
2006; Clement et al., 2003 Yamanaka et al., 2008b). Healthy cells not ex-
pressing an ALS-associated mutation could also delay degeneration and
signiﬁcantly extend the lifespan of ALS mice. In addition to chimeric
mouse studies, transplantation studies show that rodent glial cells
transplanted into animal models of ALS have a beneﬁcial effect on
motor neuron survival and animal function (Lepore et al., 2008).
However, in contrast to the positive effects from rodent-derived cells,
grafting the equivalent human-derived cell type resulted in no function-
al beneﬁts in ALS animalmodels (Suzuki et al., 2007; Lepore et al., 2011;
Hefferan et al., 2012). This lack of functional effect of the human cells
could be due to several factors: (i) Animal models have an extremely
severe and rapid disease phenotype, (ii) the amount of cells (dose) or
the number of transplant sites was insufﬁcient to protect diseased
motor neurons, (iii) human cell transplants into animals do not have
time to fully develop into the most mature and therapeutic cell type
before the diseased animal reaches the terminal stage or (iv) support
cells alone will not reduce motor neuron death in ALS.
Cell-based therapeutic approaches to ALS and other neurodegenera-
tive disorders have a long history with the use of primary fetal tissues
and more recently NSCs (Lindvall, 1991). As replacing motor neurons
in ALS is not currently practical, the focus instead is on providing
support cells, which is validated by the above studies with rodent
cells. There is also some evidence that providing new interneurons
that connect with degenerating motor neurons may have some beneﬁ-
cial effects (Xu et al., 2006; Yan et al., 2006). Thiswas the basis for one of
the ﬁrst clinical trials using stem cells for ALS as described below.
Spinal-derived neural stem cells for the treatment of ALS: Neuralstem
Clinical Trial (NSI-566RSC)
Rationale and proof-of-concept studies
NSCs can be isolated from the CNS of post-mortem fetal samples and
expanded in culture (Cattaneo and McKay, 1991; Gage et al., 1995;
Svendsen et al., 1997;Wright et al., 2006). These cells have the capacity
to become astrocytes, the most abundant cell type in the brain, as
well as neurons and in some cases, oligodendrocytes. One such cell
line, NSI-566RSC (Neuralstem, Inc.; Rockville, MD), was isolated from
an 8-week-old human fetal spinal cord and expanded in culture as a
monolayer using the FGF-2 mitogen, a method based on numerous
rodent studies. Following transplantation into the rodent spinal cord,
NSI-566RSC cells predominantly differentiated into neuronal cells ex-
pressing inhibitory (GABAergic) or excitatory (glutamatergic) cell fate
markers, with some expression of astrocyte (GFAP) or oligodendrocyte
(APC) markers (Guo et al., 2010; Yan et al., 2007). In early pre-clinical
studies, intraparenchymal transplantation of NSI-566RSC cells into the
lumbar spinal cord of SOD1G93A rat and mouse transgenic models of
ALS enhanced motor neuron survival, delayed loss of motor function
and extended lifespan by 11–12 days compared to control animals
(Xu et al., 2006; Yan et al., 2006). In addition, transplantation of NSI-
566RSC into both the lumbar and cervical spinal cord extended the sur-
vival of SOD1G93A rats by 17 days (Xu et al., 2011). Xu and colleagueshave also shown a signiﬁcant increase in the expression of BDNF,
GDNF and vascular endothelial growth factor in the spinal cords of ani-
mals grafted with NSI-566RSC, suggesting that motor neuron survival
may be attributed to increased presence of trophic factors following
transplantation (Xu et al., 2006).
Interestingly, more recent publications from the same group have
shown that these differences in lifespan could be due to comparing
treated animalswith control animals that received dead cell transplants,
which have been shown to exacerbate motor neuron death (Hefferan
et al., 2012). In continuing studies that avoided the use of dead cells in
the control group, NSI-566RSC cells transplanted into the spinal cord
of ALS rats had no signiﬁcant effect on animalmotor behavior or lifespan
(Hefferan et al., 2012). On the other hand, there was a signiﬁcant
increase in the number of spinal motor neurons at the sites of NSI-
566RSC transplantation, suggesting that NSCsmay in fact have a beneﬁ-
cial effect on ALS pathology. Therefore, the studies using NSI-566RSC
cells in ALS animal models provide some support to translate this
approach to a clinical setting.
In addition to rodent studies, the United States Food and Drug
Administration (US FDA) often requires larger animal studies prior to
clinical trials. As the pig spinal cord is similar in size to that of humans,
this is a good large animal for modeling and optimizing surgical stem
cell transplantation techniques. Validation of the surgical procedure
and device necessary for the delivery of stem cells to the spinal cord
was performed in pigs by Boulis and colleagues and shown to be safe
(Federici et al., 2012; Raore et al., 2011; Riley et al., 2009; Riley et al.,
2011).
Overview
Neuralstem, Inc. sponsored the ﬁrst Phase I US FDA-approved
clinical trial for a stem cell-based treatment of ALS. Initiated in 2010
and completed in 2013, this Phase I clinical trial involved the transplan-
tation of human spinal cord-derivedNSCs into the spinal cord of 15 late-
to mid-stage ALS patients (Glass et al., 2012; Riley et al., 2012; Riley
et al., 2014) (ClinicalTrials.gov identiﬁer: NCT01348451; see Table 2
for overview of Neuralstem Clinical Trials). This initial trial was devel-
oped to assess the safety of the surgical technique and the implantation
of human spinal cord-derived stem cells into ALS patients. This study
had an “escalation of risk” design where lumbar microinjections were
performed prior to attempts at cervical intervention and non-
ambulatory patients received grafts prior to ambulatory patients.
In the ﬁrst part of this study, 12 patients received either ﬁve unilat-
eral or ﬁve bilateral (10 total) injections of human spinal cord-derived
NSCs (NSI-566RSC line) into the lumbar region of the spinal cord
(Glass et al., 2012) (for details see Table 2). There were no long-term
surgical complications and importantly, ALS patients tolerated the pro-
cedure, gave no indications that the stem cells were injurious to the spi-
nal cord and showed no disease acceleration due to injections. As
transplantation of NSI-566RSC cells into the lumbar region appeared
to be safe, the second part of the Phase 1 trial determined the safety of
injecting cells into the C3–C5 cervical region of the spinal cord. Surgical
intervention might pose a greater risk in this region that is responsible
for respiratory and limb functions. Three newALS patients and three pa-
tients that had previously received lumbar injections received unilateral
cervical injections of NSI-566RSC cells. The primary outcome ﬁndings
show that the vulnerable spinal cord of ALS patients is capable of toler-
ating up to 15 microinjections of these NSCs (Riley et al., 2014). A few
negative events were observed following cell transplantation; however,
it was uncertain that they were directly attributed to NSI-566RSC cells.
Transient pain experienced by some patients was presumed to be asso-
ciated with the injection procedure itself. Other observed adverse ef-
fects were attributed to ALS progression and the immunosuppressive
regimen. There were some hints of positive effects (slowed rate of
progression), particularly in patients with non-bulbar onset of disease,
and one patient appeared to show an improvement in clinical status.
However, one of the complications of small studies such as these is
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sive to the powerful immune-suppression regimes. Thus, these reports
must be treated as anecdotal until conﬁrmed in larger groups of
patients.
The conclusion from this completed Phase I trial is that unilateral
and bilateral transplantation of these human NSCs into the spinal cord
of ALS patients is remarkably safe (given the invasive surgical tech-
niques used) and very well-tolerated. It was also of note that there
was no obvious deterioration in patient progression — an important
possible outcome of infusions of cells into the fragile spinal cord of
ALS patients. Based on these positive results, a Phase II study was
initiated in September, 2013 to deﬁne a maximum tolerated dose of
NSI-566RSC cells in ALS patients. Fifteen patients in ﬁve different dosing
cohorts will receive advancing doses of up to a maximum of 40 injec-
tions and 400,000 cells per injection (Table 2). The ﬁrst 12 patients
will receive injections in the cervical spinal cord and the ﬁnal three
patients will receive both cervical and lumbar injections (Clinical trial
identiﬁer: NCT01730716).
Although theNeuralstem, Inc clinical studies are encouraging for ALS
patients and the stem cell transplantation ﬁeld, a number of challenges
remain to be addressed.Most important of these are related to theman-
agement of adverse effects associated with chronic immune suppres-
sion of transplanted patients. This resulted in a number of patients in
the Neuralstem trial being taken off their suppression due to severe
side-effects. Interestingly, in two Parkinson's disease patients having re-
ceived fetalmidbrain transplants in the striatumor substantia nigra and
receiving standard immunosuppression for a period of only 6 months,
grafts were observed at post-mortem analysis 3–4 years following
transplantation surgery (Mendez et al., 2005). This study seems to indi-
cate that transient immune suppression may be sufﬁcient to enable the
survival of fetal grafts in the brain. Furthermore, in one notable study,
patients who had received no immune suppression following fetal do-
pamine neuron transplants showed surviving grafts up to 14 years
after surgery (Freed et al., 2011). While primary fetal tissue may be
very different immunogenically to expanded populations of NSCs, this
study at least shows that the brain is an immunologically privileged
site and more studies need to be performed to assess allograft survival
in humans.Glial restricted progenitor transplantation
Glial restricted progenitor (GRP) cells have the ability to adopt the
fate of astrocytes or oligodendrocytes following differentiation in vitro
or in vivo (Sandrock et al., 2010). In an initial study, GRPs were isolated
from the rat embryonic spinal cord, sorted for the GRP-speciﬁc cell
surface antigen A2B5, immortalized with the V-myc oncogene and
engineered to express a reportermarker (Lepore et al., 2008). Following
expansion in culture, GRPs were bilaterally transplanted into the cervi-
cal spinal cord parenchyma of the SOD1G93A ratmodel of ALS. At disease
end-stage, there was robust survival of GRPs with differentiation into
GFAP-expressing astrocytes in vivo. ALS rats grafted with GRPs showed
a 1.5 fold increase in the number of motor neurons and a decrease in
microgliosis compared to rats transplanted with dead cells. Additional-
ly, ALS rats receiving GRP transplants exhibited a slower decline of grip
strength, improved motor function score, a 16.9-day extension in
lifespan and recording of compound action potentials in the phrenic
nerve revealed better maintenance of diaphragm function compared
to media and dead-cell transplanted control rats. A subsequent study
assessed stem cell-derived astrocytes for the treatment of ALS by
transplanting Q-Therapeutics' Q-Cells®, or human GRPs derived from
the human fetal forebrain, into the cervical spinal cord of the
SOD1G93A mouse model of ALS. Although grafted Q-Cells survived and
predominantly differentiated into GFAP-expressing astrocytes in vivo,
they had no effect on lifespan, motor behavior ormotor neuron survival
(Lepore et al., 2011).The differing results from these two GRP transplantation studies
may be due to the severity of the SOD1G93A mouse model of ALS com-
pared to the less severe rat model, variation in the quantity of grafted
cells, and several differences in cell type (rat versus human; spinal- ver-
sus forebrain-derived; allograft versus xenograft) including the slower
rate of maturation of human cells compared to those derived from ro-
dents. Despite the differences in results and the lack of a phenotypic ef-
fect, Q-Cells provided valuable insight into the fate of human GRPs
transplanted into an ALS animal model. Additionally, no tumor forma-
tion or heterotopic engraftment was observed in the animals up to
3 months post-transplantation, an important ﬁnding for translation to
the clinic. Due to the beneﬁcial effects observed following the transplan-
tation of the rodent GRPs and the apparent safety of the approach, pre-
clinical studies are ongoing to permit Q Therapeutics to ﬁle an Investiga-
tional New Drug for clinical testing of Q-Cells for the treatment of
patients with ALS.
Neural progenitor cells producing GDNF: An ex vivo gene therapy approach
In another approach, we have extensively studied human fetal
cortex-derived neural cells that are cultured as 3-dimensional aggre-
gates termed “neurospheres” in the presence of mitogens and passaged
via a mechanical chopping method. At later passages, these cells differ-
entiate in vitro into astrocytes and some neurons, but not oligoden-
drocytes. Consequently, they are deﬁned as bipotent neural progenitor
cells (NPCs) rather than multipotent NSCs. Following transplantation
into the CNS, cells preferentially differentiate into GFAP-expressing
astrocytes, although neurons can arise when younger passages are
transplanted (Fricker et al., 1999; Ostenfeld et al., 2000; Svendsen
et al., 1997). However, transplantation of these human NPCs (hNPCs)
into the lumbar spinal cord of the SOD1G93A rat model did not lead to
phenotypic functional beneﬁt or enhanced motor neuron survival
(Klein et al., 2005; Suzuki et al., 2007). Conversely, cervical transplanta-
tion of these cells into the same ALS model speciﬁcally promoted the
survival and the function of phrenic motor neurons ipsilateral to the
transplant (Nichols et al., 2013).
Many stem cell transplantation studies involving animal models of
CNS disease have attributed observed beneﬁcial effects to grafted cells
producing trophic factors, immunomodulatory molecules or other neu-
roprotective factors (Gowing and Svendsen, 2011). We have previously
shown that hNPCs can be genetically engineered to stably secrete neu-
rotrophic factors in vivo (Fig. 1) (Ebert et al., 2008; Ostenfeld et al.,
2000). In the context of motor neuron disease, GDNF initially attracted
interest in 1994 because of its potent capability to enhance the survival
ofmotor neurons in vitro and in vivo (Henderson et al., 1994). Unilateral
transplantation of hNPCs secreting GDNF in the lumbar spinal cord
of SOD1G93A transgenic rats resulted in a 3-fold greater number of sur-
viving motor neurons ipsilateral to the graft compared to animals
transplanted with control, non-GDNF-secreting hNPCs (Suzuki et al.,
2007). Despite this signiﬁcant increase in motor neuron survival, there
was no functional beneﬁt of GDNF-producing hNPCs onmotor behavior
or neuromuscular innervation. Interestingly, similar to the results ob-
tainedwith hNPCs alone, unilateral transplantation of hNPCs expressing
GDNF into the cervical spinal cord of ALS rats resulted in improved
phrenic motor output at baseline compared to the contralateral non-
transplanted side (Nichols et al., 2013). Recently, we have shown that
hNPCs engineered to express GDNF survive long-term (7.5 months) fol-
lowing transplantation into the spinal cord of athymic nude rats and
continue to secrete GDNF (Gowing et al., 2013).
Based on the results from these animal studies, hNPCs expressing
GDNF are being pursued for clinical translation. A master cell bank of
hNPCs generated under good manufacturing practice (GMP) has been
produced and the expansion of clinical-grade lots of hNPCs transduced
with a GMP-grade lentivirus encoding GDNF is currently ongoing.
Prior to ﬁling for an Investigational New Drug, four steps remain:
(i) determination of the optimal effective and maximum feasible dose
Table 2
Neuralstem clinical trial patient summary.
Phase I
Each injection administered to patients contained approximately 100,000 cells in an 8.5–10 μL volume.
Group Spinal cord region Disease condition Total # of injections
A1 Unilateral/lumbar (L2–L4) Nonambulatory 5
A2 Bilateral/lumbar (L2–L4) Nonambulatory 10
B Unilateral/lumbar (L2–L4) Ambulatory 5
C Bilateral/ lumbar (L2–L4) Ambulatory 10
D Unilateral/cervical (C3–C5) Ambulatory 5
E* Unilateral/cervical (C3-C5) Ambulatory 5
* Patients in Group E were the same patients as in Group C, receiving additional injections at a later time point, for a total # of 15 injections.
Phase II
All patients in Phase II are ambulatory, early-stage with arm weakness, but not paralysis, receiving bilateral injections of varying cell doses suspended in an 8.5–10 μL volume.
Group Spinal cord region Total # of cells Total # of injections
A Cervical C3–C4 2,000,000 10 (200,000 cells/injection)
B Cervical C3–C5 4,000,000 20 (200,000 cells/injection)
C Cervical C3–C5 6,000,000 20 (300,000 cells/injection)
D Cervical C3–C5 8,000,000 20 (400,000 cells/injection)
E Lumbar L2–L5, followed 4–12 weeks later with cervical C3–C5 160,000,000 40 (400,000 cells/injection)
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igenicity testing in immune-compromised rats and (iv) determination
of the safety of cells and surgical approach in Yucatan mini-pigs as a
pre-clinical model. The ﬁnal goal is FDA approval of a Phase I/IIa trial
with 18 patients receiving unilateral lumbar hNPC-GDNF transplants
and systematic clinical assessment over a 12-month period.
Vescovi Clinical Trial
There is also one small trial currently being conducted by the
Vescovi group from Azienda Ospedaliera Santa Maria, using NSCs
derived from human fetal tissues (Gelati et al., 2013) for injection into
the lumbar spinal cord of ALS patients in Italy. We could not ﬁnd any
pre-clinical published data to support this trial, however, it is listed on
Clincialtrials.gov (ClinicalTrials.gov Identiﬁer: NCT01640067).
Discussion: Considerations for future clinical trials
Importance of pre-clinical studies
Stem cell-based therapies come with multifaceted considerations
regarding safety, cell availability, immune rejection and ethics in the
case of embryonic- or fetal-derived cells (Aboody et al., 2011; Hyun
et al., 2008; Lindvall and Kokaia, 2010; Lindvall et al., 2012). However,
in devastating diseases such as ALS, where there is no prevention or ef-
fective treatment, clinicians and patients are likely willing to take more
risks in their treatment options. Nonetheless, prior to clinical translation
for ALS, scientiﬁc evidence must support the ability of the proposed
treatment to either replace degenerating motor neurons or promote
their survival and function (Lindvall et al., 2012). Unfortunately, thera-
peutic strategies that showed efﬁcacy and promise in ALS animal
models were less efﬁcient in clinical trials. While this dichotomy sug-
gests little value of proof-of-concept pre-clinical studies, it is also true
that studies in animal models are often insufﬁciently powered, poorly
controlled and rarely reproduced in identical or additional disease-
speciﬁc models prior to pursuing clinical translation (Schnabel, 2008;
Scott et al., 2008).
To identify therapeutic strategies pertinent to the human condition,
it is essential to have rigorous and appropriately designed translational
studies that have strong rationales and that consider the deliverymeth-
od, treatment timing, critical controls, and relevant functional outcome.
For example, recent trials usingminocycline highlight the importance of
incorporating multiple time points in pre-clinical studies. Threeindependent studies showed minocycline treatment before the onset
of overt ALS symptoms slowed disease progression in mutant SOD1
transgenic mice (Kriz et al., 2002; Van Den Bosch et al., 2002; Zhu
et al., 2002). However, a randomized placebo-controlled Phase III trial
conversely revealed that minocycline administration accelerated the
decline of ALS patients (Gordon et al., 2007). This reversed effect of
minocycline given to post-symptomatic patients was subsequently val-
idatedwhenALSmice treatedwithminocycline after the onset of symp-
toms showed no increase in survival (Keller et al., 2011). Clearly,
multiple time points alongwithmany other aspects need to be carefully
consideredwhen using animal models for translation to clinical studies.Inclusion of placebo/sham patient groups
There have been many discussions regarding the use of placebo pa-
tient groups in clinical trials involving complex and risky surgical proce-
dures. Obviously this would increase conﬁdence in the outcome being
related to the implanted cells rather than simply to the injected vehicle.
However, putting patients through such high-risk surgical procedures
without possible beneﬁt may not be acceptable to some Institutional
Review Board committees. The Neuralstem Inc. trial did not have a pla-
cebo group, nor have any of the other transplant trials for ALS discussed
in this review as far aswe can establish. Interestingly, the use of targeted
delivery of stem cells to restricted regions of the CNS allows for more
creative clinical trial designs, which both increase the power of the
study and bring in a placebo control. In our own planned trial, GDNF-
secreting stem cells will be transplanted only unilaterally into the
lumbar spinal cord of ALS patients. While the neurosurgeons will
know the transplanted side, the neurologists and patients will be
blinded. This will allow the progression in both legs to be monitored
over-time to establish whether the cell transplant had any effect on
the treated side, without confounds from the patient knowing which
leg may be expected to improve. While this is not a full placebo
controlled trial (for this we would need to inject vehicle into the non-
treated side) it does allow a blinded trial to occur through localized
unilateral delivery of the cells. Typically in ALS, slow or fast paralysis
progression in one leg predicts a similar paralysis progression in the
other leg. This allows for a strong prediction of leg paralysis progression
in the same patient and, importantly, a determination of whether the
leg paralysis progression is affected by unilateral cell transplants. This
increases the power of the trial signiﬁcantly when compared to trials
involving many patients with very different progression rates.
Fig. 1. Representative images of GDNF-expressing hNPCs transplanted in the rat spinal cord using human-speciﬁc antibodies. (A–C) Immunostaining for a human-speciﬁc cytoplasmic
marker (red; STEM121, Stem Cells Inc.) and GDNF (green; R&D) at (A) 10× and (B) 40×. Notice the presence of GDNF in neuronal cell bodies (white arrows) and (C) lack of staining
in the ventral horn contralateral to transplant. (D) Human nuclei stain (red; Ku80 antigen, STEM101, Stem Cells Inc.) and labeling for the motor neuron marker choline acetyltransferase
(green; ChAT; AB144P, Millipore) showing the localization of the transplants in the spinal cord ventral horn. (E) Human-speciﬁc nestin (red; ABD69, Millipore) and human-speciﬁc GFAP
(STEM123 Stem Cells Inc.) showing the in vivo phenotype of the grafted cells.
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A key challenge for stem cell-based therapeutic approaches is the
need for reliable tracking of grafted cells. The ability to localize
transplanted cells using imaging technologies would beneﬁt the assess-
ment of targeting and safety of the cells. Currently, radiolabelling cells
with ﬂurodeoxyglucose, indium or technetium and subsequent PET or
SPECT imaging appears to be themost commonly used clinical approach
(McColgan et al., 2011). However, the short half-life of the clinically
approved molecules limits the capacity for long-term imaging. More-
over, the poor spatial resolution of acquisition techniques combined
with the possible deleterious effects of ionizing compounds results in
low appeal of these methods for CNS transplantation (McColgan et al.,
2011). Another approach is iron-oxide-labeling of cells formagnetic res-
onance imaging (MRI). Although offeringhigh resolution, the sensitivity
of this modality is low. The most commonly used compounds are
superparamagnetic iron oxide (SPIO) or ultrasmall SPIO nanoparticles.
Some studies have shown encouraging data for tracking of NSCs
following intravenous or intraparenchymal injection (Deng et al.,
2013; Gutova et al., 2013), but our unpublished data (Bernau et al, man-
uscript in progress) and that of others have suggested that the T2-
weighted MR signal or detection of iron deposits via Prussian blue stain,
is not necessarily indicative of the presence of live cells (Sadan et al.,
2009). Interestingly, in one study, the transplantation of cells labeled
with bimodal MRI contrast agent, a Gadolinium–RhodamIne Dextran
conjugate, abolished behavioral improvements and the reduction in
lesion size compared to control rodents receiving unlabeled NSCs
(Modo et al., 2009). Clearly, having the ability to use imaging modalities
in the clinic to track cells following transplantationwould be a signiﬁcant
advancement to the ﬁeld. However, when considering labeling strategies,
prior tomoving to the clinic, it is important to consider the overall effect ofthe label on cell viability both in vitro and in vivo, the possibility of any
CNS toxicity and the speciﬁcity of the label for identifying live (versus
dead) cells.
Clinical trial design strategies
Biomarkers
Another important consideration for stem cell-based therapies is
the overall clinical trial design. Biomarkers can indicate the biologi-
cal effects of grafted cells on disease manifestation and can help pre-
dict the outcome on motor function during the patient's lifespan
essential for indicating the biological effects of grafted cells on dis-
ease processes as well as for assisting in determining the outcome
on patient motor function (Bruijn and Cudkowicz, 2014; Turner
et al., 2013). Various tissues and ﬂuids can be used to identify bio-
markers including cerebral spinal ﬂuid (CSF), blood, urine, saliva,
muscle and skin (Turner et al., 2013). Currently the most promising
biomarkers are found in the CSF and include those that are indicative
of neuronal loss or neuroinﬂammatory processes (Ganesalingam et al.,
2011; Puentes et al., 2014; Sussmuth et al., 2008). Measures of motor
function such as motor unit number estimation, motor unit number
index, and electrical impedance myography may also be valuable for
potentially monitoring disease progression and therapeutic effects
(Bromberg, 2013; Furtula et al., 2013; Nandedkar et al., 2004; Rutkove
et al., 2014). However the majority of these markers have yet to be
fully validated for routine use in ALS Clinical Trials.
Route/location of administration
The route of cell administration to patients is clearly of vital impor-
tance. There is little published evidence that cells delivered via any
route other than direct parenchymal injection can get deep into the
Fig. 2. Summary of clinical trials involving stemcells and gene therapy for the treatment of
ALS. Schematic shows the regions affected byALS including the brain, spinal cord and skel-
etal muscle and highlights the current and developing therapies to target these regions.
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Thus the most reliable technique remains direct injection of the cells
into the spinal cord.
Interestingly, there have been no well-designed treatment strat-
egies targeting the upper motor neurons in ALS patients. While little
is known about brain pathology in ALS, a number of studies in both
animal models and in patients propose that hyperexcitability and/or
corticospinal motor neuron degeneration observed presymptomatically
may be the initial trigger to disease onset (Ozdinler et al., 2011; Vucic
et al., 2008). While many of the current stem cell-based therapies target
spinal motor neurons, therapeutic beneﬁt may also result from targeting
corticospinal motor neurons using cell therapy and growth factors. It is
also likely that a combined approach, inwhichmultiple pathways and re-
gions within the CNS/skeletal muscle are targeted simultaneously or in a
well-designed time course, will bemost successful in treating the disease.
For instance, while transplanted neural progenitors secreting GDNF can
promote the survival of spinal motor neurons, functional outcome is not
altered in this model due to downstream disjunction of muscle endplates
that have not been targeted and therefore not spared (Suzuki et al., 2007).
In a different approach, we have shown that MSC transplants in themuscle of ALS rats resulted in a mild amelioration of motor neuron func-
tion. This effect was enhanced following the transplantation of MSCs
engineered to produce GDNF, which also resulted in an increased lifespan
of the treated ALS rats (Krakora et al., 2013; Suzuki et al., 2008). Thus, it is
possible that combining these various therapeutic approacheswould lead
to increased beneﬁcial effects (Fig. 2).
Conclusions
Prior to initiating future clinical trials, proof-of-concept data must
show that the stem cells can be targeted to the therapeutic areawithout
any adverse effects. Pre-clinical and clinical trials with both MSCs and
NSCs indeed suggest that novel stem cell therapeutic approaches are
safe and feasible. Some stem cell approaches in animal models provide
a strong rationale and evidence to suggest that stem cell therapy has
great potential to delay motor neuron degeneration and potentially en-
hance function in ALS patients. While not all pre-clinical animal models
support this hypothesis, it should be considered that these models are
subject to many limitations such that ﬁnal proof may require conﬁrma-
tion in humans affected by the disease. Indeed, based on the current
safety of new stem cell transplantation approaches for ALS, this review
highlights that it is now time to move promising stem cell-based
therapies into the clinic in order to really understand whether they
may work in patients.
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